Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus. Dermatol Reports [Internet]. 2025 Sep. 11 [cited 2025 Oct. 9];. Available from: https://journals.pagepress.org/dr/article/view/10458